drugset / Trial / NCT07230730
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.
Timeline
- Start
- 2026-01-13
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-1918 | Monoclonal antibody | — | — |